

## APAS® INDEPENDENCE SHOWCASED AT MAJOR US MICROBIOLOGY CONFERENCE

*Independent clinical data supporting APAS® Independence presented at ASM Microbe 2022*

**Adelaide, Australia, 14 June 2022:** Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to announce the presentation of the APAS® Independence at the American Society of Microbiology annual conference (ASM Microbe), in Washington D.C., United States from 9 - 13 June 2022.

### Key Points:

- **APAS® Independence on display and featured on Thermo Fisher exhibitor booth**
- **“Accelerating the impact through AI and digital imaging” APAS® workshop well attended**
- **Two publications featuring APAS® Independence presented at the conference**
- **New clinical data from Hennepin County Medical Center and University of California San Diego**

ASM Microbe is the largest annual conference for microbiology held in the United States, providing a full scientific program covering the latest innovations from around the world. This year’s conference was held in person for the first time in two years in Washington D.C., United States from 9 – 13 June 2022.

The APAS® Independence was showcased on the Thermo Fisher Scientific (Thermo Fisher) booth for the first time and was featured alongside Thermo Fisher’s suite of infectious disease testing solutions. During the conference, Thermo Fisher hosted an educational workshop on laboratory automation in microbiology. The workshop, presented by key opinion leaders Dr Hilmar Wisplinghoff (Labor Dr Wisplinghoff, DE) and Jacqueline Getty (Hennepin County Medical Center, US), discussed the ability of artificial intelligence and digital imaging to maximise the benefits of automation within the clinical microbiology laboratory.

A photo of the Thermo Fisher booth is attached to this ASX release.

LBT CEO and Managing Director, Mr Brent Barnes said:

*“The Thermo Fisher booth is truly impressive, they have one of the largest trade presences at the conference located in a prime position that is impossible to miss. It was fantastic to see the APAS® Independence on their stand and to see the interaction of customers with their sales teams.”*

### Clinical Data Presented at ASM Microbe 2022

During the conference there were two posters featuring the APAS® technology presented as part of the scientific program. The posters presented new independent clinical data from US laboratories assessing the performance of the APAS® Independence for Urine culture screening.

#### **Comparison of the APAS Independence automated plate reader system with manual standard-of-care for processing urine culture specimens**

*P. Kuo<sup>1</sup>, K. Lecrone<sup>1</sup>, D. T. Pride<sup>2</sup>;*

*1. UCSD, San Diego, CA, 2. UCSD, La Jolla, CA*

#### **Evaluation of the APAS Independence as an artificial intelligence tool for urine culture reporting in a clinical hospital setting**

*J. Getty<sup>1</sup>, A. Nussbaum<sup>1</sup>, E. Wesenberg<sup>2</sup>, S. Giglio<sup>3</sup>, G. Hansen<sup>1</sup>;*

*1.Hennepin County Med. Ctr., Minneapolis, MN, 2.Hennepin County Med. Ctr., Minneapolis, MN, 3.Clever Culture Systems, Australia*

LBT Scientific Director, Dr Steven Giglio said:

*“Urine cultures are typically the highest volume test conducted in the clinical microbiology laboratory. Both presentations continue to demonstrate the high accuracy of the APAS® Independence when removing negative plates from the workflow, reducing hands on time, and resulting in workflow efficiencies. At a time when there are critical skill shortages in this area, the implementation of technologies such as the APAS® Independence are clearly showing an advantage.”*

Both posters will be made available on the Company website under the Scientific Library section once they become publicly available (<https://lbtinnovations.com/products/scientific-library/>).

Approved for release by the Chair of the LBT Board.

– ENDS –

#### **About LBT Innovations**

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Channel partners for the sale and distribution of the APAS® Independence are in place for the United States (Thermo Fisher Scientific, Inc; Exclusive Distributor) and Europe (Beckman Coulter, Inc; Marketing Agent).

#### **INVESTOR ENQUIRIES**

<b>LBT Innovations</b>
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>

# ASM Microbe 2022

APAS® Independence showcased on Thermo Fisher booth

